Pharmaceutical firm, Pfizer has been fined a record $106. 54 million by the Britain’s competition watchdog for ramping up the cost of an epilepsy drug by as much as 2,600 percent it said on Wednesday
The Competition and Markets Authority also fined Flynn Pharma 5.2 million pounds for its role in hiking prices of Phenytoin sodium capsules in 2012.
Pfizer used to market the medicine itself, under the brand name Epanutin, but sold the rights to Flynn in September 2012, after which the product was re-branded and the price soared.
